Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer
NCT ID: NCT01119573
Last Updated: 2010-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying at biomarkers in tissue samples from patients with stage I or stage III endometrial cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer
NCT01150682
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
NCT01198171
Biomarkers in Samples From Patients With Endometrial Cancer
NCT01199250
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
NCT01344837
Estrogen, Diet, Genetics and Endometrial Cancer
NCT00587886
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To identify microRNA expression patterns associated with lymph node metastasis in samples from patients with endometrial cancer.
OUTLINE: Banked tumor tissue specimens are analyzed for microRNA expression profiling by microarray analysis and reverse transcriptase-PCR assays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
microarray analysis
reverse transcriptase-polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed endometrioid endometrial cancer
* Stage IA, IB, IC, or IIIC disease
* Any grade
* Enrolled and evaluated on GOG-0210 Molecular Staging Study of Endometrial Cancer
* Consented to allow their specimens and clinical data to be collected and stored for future research
* Underwent complete surgical staging, including the following:
* Hysterectomy
* Bilateral oophorectomy
* Washings as well as pelvic lymphadenectomy (sampling of four left and four right pelvic lymph nodes)
* Para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph node)
* Sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity and ≤ 10% necrosis
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Gynecologic Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gynecologic Oncology Group
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David S. Miller, MD
Role: PRINCIPAL_INVESTIGATOR
Simmons Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GOG-8014
Identifier Type: -
Identifier Source: secondary_id
CDR0000672415
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.